ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
MetaVia Inc. A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.	United States of America	MTVA
Metsera, Inc. Develops potent, long-acting oral & injectable therapies for obesity & metabolic diseases.	United States of America	MTSR
Mezzion Pharma Co., Ltd. Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.	South Korea	140410
MFC Co., Ltd. A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.	South Korea	432980
Milestone Pharmaceuticals Inc. Developing a self-administered nasal spray for at-home treatment of acute cardiac events.	United States of America	MIST
MIMEDX GROUP, INC. Provides placental-based biologics for advanced wound care, surgical, and burn applications.	United States of America	MDXG
Mind Medicine (MindMed) Inc. Developing psychedelic-inspired medicines and novel therapies for brain health disorders.	United States of America	MNMD
Mineralys Therapeutics, Inc. Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.	United States of America	MLYS
MiNK Therapeutics, Inc. Developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.	United States of America	INKT
MIRA PHARMACEUTICALS, INC. Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.	United States of America	MIRA